Literature DB >> 19922948

Mesenteric nitric oxide and superoxide production in experimental necrotizing enterocolitis.

Jill S Whitehouse1, Hao Xu, Yang Shi, LeAnne Noll, Sushma Kaul, Deron W Jones, Kirkwood A Pritchard, Keith T Oldham, David M Gourlay.   

Abstract

BACKGROUND: A proposed mechanism of intestinal injury in necrotizing enterocolitis (NEC) involves vascular dysfunction through altered nitric oxide synthase (NOS) activity. We hypothesize that this dysfunction results in an imbalance in nitric oxide (*NO) and superoxide (O(2)(*-)) production by the intestinal vascular endothelium, which contributes to the intestinal injury seen in NEC.
MATERIALS AND METHODS: Neonatal rat pups were divided into two groups. Control pups were breast fed and housed with their mother. Experimental NEC pups were housed separately and either exposed to formula feeding and 5% to 10% hypoxia alone (FF/H) or with the addition of lipopolysaccharide (FF/H/LPS). Mesenteries from each group were analyzed for *NO and O(2)(*-) production with and without NOS inhibition by N(G)-monomethyl-L-arginine (L-NMMA). Western blot analysis for eNOS, phosphorylated eNOS (phospho-eNOS), and inducible NOS (iNOS) was performed, and each terminal ileum was graded for intestinal injury by histology.
RESULTS: Histology revealed mild intestinal injury (grade 1-2 on a 4-point scale) in the FF/H group and severe injury (grade 3-4) in the FF/H/LPS group. The FF/H cohort had significantly increased *NO and lower O(2)(*-) production, while the FF/H/LPS group shifted to significantly decreased *NO and increased O(2)(*-) production. L-NMMA inhibited >50% of O(2)(*-) production in all three groups but only inhibited *NO production in control and FF/H pups. Western blot analysis revealed increased levels of phospho-eNOS in FF/H pups and increased iNOS in FF/H/LPS pups.
CONCLUSIONS: This study demonstrates in the progression of NEC, intestinal ischemia is associated with a shift from *NO to O(2)(*-) production, which is NOS-dependent. Potentially greater injury results from impaired vasodilatation and over-production of reactive oxygen species. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922948      PMCID: PMC3196648          DOI: 10.1016/j.jss.2009.07.028

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  31 in total

1.  Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model.

Authors:  Bohuslav Dvorak; Melissa D Halpern; Hana Holubec; Catherine S Williams; Debra L McWilliam; Jessica A Dominguez; Renata Stepankova; Claire M Payne; Robert S McCuskey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-01       Impact factor: 4.052

2.  Revisiting ischemia and reperfusion injury as a possible cause of necrotizing enterocolitis: Role of nitric oxide and superoxide dismutase.

Authors:  K L Chan; Connie W C Hui; K W Chan; Peter C W Fung; Jana Y H Wo; G Tipoe; Paul K H Tam
Journal:  J Pediatr Surg       Date:  2002-06       Impact factor: 2.545

3.  Arginine supplementation prevents necrotizing enterocolitis in the premature infant.

Authors:  Harish J Amin; Samuel A Zamora; Douglas D McMillan; Gordon H Fick; J Decker Butzner; Howard G Parsons; R Brent Scott
Journal:  J Pediatr       Date:  2002-04       Impact factor: 4.406

4.  Prolactin activation of mammary nitric oxide synthase: molecular mechanisms.

Authors:  F F Bolander
Journal:  J Mol Endocrinol       Date:  2002-02       Impact factor: 5.098

5.  Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase.

Authors:  Tomasz J Guzik; Shafi Mussa; Daniela Gastaldi; Jerzy Sadowski; Chandi Ratnatunga; Ravi Pillai; Keith M Channon
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

Review 6.  Role of nitric oxide and peroxynitrite in gut barrier failure.

Authors:  Douglas A Potoka; Evan P Nadler; Jeffrey S Upperman; Henri R Ford
Journal:  World J Surg       Date:  2002-04-15       Impact factor: 3.352

Review 7.  Enzymatic function of nitric oxide synthases.

Authors:  P J Andrew; B Mayer
Journal:  Cardiovasc Res       Date:  1999-08-15       Impact factor: 10.787

8.  Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme.

Authors:  Chun-An Chen; Lawrence J Druhan; Saradhadevi Varadharaj; Yeong-Renn Chen; Jay L Zweier
Journal:  J Biol Chem       Date:  2008-07-13       Impact factor: 5.157

9.  Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells.

Authors:  Hanke Mollnau; Eberhard Schulz; Andreas Daiber; Stephan Baldus; Matthias Oelze; Michael August; Maria Wendt; Ulrich Walter; Carolin Geiger; Rahul Agrawal; Andrei L Kleschyov; Thomas Meinertz; Thomas Münzel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-06       Impact factor: 8.311

10.  Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression.

Authors:  Nicholas J Alp; Shafi Mussa; Jeffrey Khoo; Shijie Cai; Tomasz Guzik; Andrew Jefferson; Nicky Goh; Kirk A Rockett; Keith M Channon
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  12 in total

1.  Tissue protection and endothelial cell signaling by 20-HETE analogs in intact ex vivo lung slices.

Authors:  Elizabeth R Jacobs; Sreedhar Bodiga; Irshad Ali; Aaron M Falck; John R Falck; Meetha Medhora; Anuradha Dhanasekaran
Journal:  Exp Cell Res       Date:  2012-06-09       Impact factor: 3.905

Review 2.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

3.  Intestinal alkaline phosphatase to treat necrotizing enterocolitis.

Authors:  Ben E Biesterveld; Shannon M Koehler; Nathan P Heinzerling; Rebecca M Rentea; Katherine Fredrich; Scott R Welak; David M Gourlay
Journal:  J Surg Res       Date:  2015-02-19       Impact factor: 2.192

Review 4.  Inflammatory signaling in necrotizing enterocolitis.

Authors:  Isabelle G De Plaen
Journal:  Clin Perinatol       Date:  2013-01-17       Impact factor: 3.430

5.  Single-Immunoglobulin Interleukin-1-Related Receptor regulates vulnerability to TLR4-mediated necrotizing enterocolitis in a mouse model.

Authors:  Jason Fawley; Alain Cuna; Heather L Menden; Steven McElroy; Shahid Umar; Scott R Welak; David M Gourlay; Xiaoxia Li; Venkatesh Sampath
Journal:  Pediatr Res       Date:  2017-10-04       Impact factor: 3.756

6.  Dithizone-induced Paneth cell disruption significantly decreases intestinal perfusion in the murine small intestine.

Authors:  Jennifer N Berger; Huyiu Gong; Misty Good; Steven J McElroy
Journal:  J Pediatr Surg       Date:  2019-02-23       Impact factor: 2.545

Review 7.  Future applications of antioxidants in premature infants.

Authors:  Jennifer W Lee; Jonathan M Davis
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

Review 8.  Oxygen radical disease in the newborn, revisited: Oxidative stress and disease in the newborn period.

Authors:  Marta Perez; Mary E Robbins; Cecilie Revhaug; Ola D Saugstad
Journal:  Free Radic Biol Med       Date:  2019-04-05       Impact factor: 7.376

9.  Changes in plasma and urinary nitrite after birth in premature infants at risk for necrotizing enterocolitis.

Authors:  Priti Pun; Jesica Jones; Craig Wolfe; Douglas D Deming; Gordon G Power; Arlin B Blood
Journal:  Pediatr Res       Date:  2015-11-05       Impact factor: 3.756

10.  Intestinal NADPH oxidase 2 activity increases in a neonatal rat model of necrotizing enterocolitis.

Authors:  Scott R Welak; Rebecca M Rentea; Ru-Jeng Teng; Nathan Heinzerling; Ben Biesterveld; Jennifer L Liedel; Kirkwood A Pritchard; Katherine M Fredrich; David M Gourlay
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.